← Eichor
Condition: Unresectable Locally Advanced Colorectal Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Locally Advanced Colorectal Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108
Phase 3 · 217 location(s) · Merck Sharp & Dohme LLC · NCT06997497A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorec
Phase 1/Phase 2 · 9 location(s) · Brenus Pharma · NCT06934538GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1 · 6 location(s) · Angiex, Inc. · NCT06440005A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresecta
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT07042685A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Phase 1 · 21 location(s) · ArriVent BioPharma, Inc. · NCT07066657Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
NA · 1 location(s) · Sichuan Cancer Hospital and Research Institute · NCT06244537A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Phase 2 · 2 location(s) · Buzzard Pharmaceuticals · NCT06634875A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07050394A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Astellas Pharma Global Development, Inc. · NCT07488676Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 · 20 location(s) · Astellas Pharma Inc · NCT07094204
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.